PDF(Pubmed)
Abstract：
UNASSIGNED: Chemotherapy-induced cognitive impairment (CICI), termed \"chemobrain\", is highly prevalent in cancer patients following the administration of chemotherapeutic agents. However, the potential pathophysiological mechanisms underlying CICI remain unknown. This study aimed to explore the functional changes of the brain and associated cognitive impairment in non-small cell lung cancer (NSCLC) patients receiving different chemotherapy regimen.
UNASSIGNED: A total of 49 NSCLC patients (25 patients receiving pemetrexed plus carboplatin chemotherapy (PeCC) and 24 patients receiving paclitaxel plus carboplatin chemotherapy (PaCC)) and 61 healthy controls (HCs) were recruited and underwent resting-state functional magnetic resonance imaging (rs-fMRI) scanning, as well as cognitive function tests including Mini Mental State Exam (MMSE), Montreal Cognitive Assessment (MoCA), Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog). Brain functional activities were measured by regional homogeneity (ReHo) values, which were calculated and compared between groups. In addition, the associations between ReHo values of changed brain regions and scores of cognitive scales were evaluated.
UNASSIGNED: NSCLC patients showed decreased scores of MMSE, MoCA and FACT-Cog and decreased ReHo values in the bilateral superior frontal gyrus (medial), middle frontal gyrus, left inferior frontal gyrus (orbital part) and increased ReHo values in the bilateral insula and caudate. Compared with HCs, patients receiving PeCC demonstrated decreased ReHo values in the right superior frontal gyrus (dorsolateral), left superior frontal gyrus (medial orbital), middle frontal gyrus, insula and rectus gyrus while patients receiving PaCC presented increased ReHo values in the right rolandic operculum, left insula and right caudate. Compared with patients receiving PaCC, patients receiving PeCC had decreased ReHo values in the left superior frontal gyrus (orbital part), middle frontal gyrus and increased ReHo values in the left inferior temporal gyrus, lingual gyrus. Moreover, positive relationships were found between ReHo values of the left and right superior frontal gyrus (medial) and the total scores of FACT-Cog in the patient group.
UNASSIGNED: The findings provided evidences that carboplatin-based chemotherapy could cause CICI accompanied by functional changes in the prefrontal cortex, insula, caudate. These might be the pathophysiological basis for CICI of NSCLC patients and were affected by the differences of chemotherapeutic agent administration through different biological mechanisms.
UNASSIGNED: A total of 49 NSCLC patients (25 patients receiving pemetrexed plus carboplatin chemotherapy (PeCC) and 24 patients receiving paclitaxel plus carboplatin chemotherapy (PaCC)) and 61 healthy controls (HCs) were recruited and underwent resting-state functional magnetic resonance imaging (rs-fMRI) scanning, as well as cognitive function tests including Mini Mental State Exam (MMSE), Montreal Cognitive Assessment (MoCA), Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog). Brain functional activities were measured by regional homogeneity (ReHo) values, which were calculated and compared between groups. In addition, the associations between ReHo values of changed brain regions and scores of cognitive scales were evaluated.
UNASSIGNED: NSCLC patients showed decreased scores of MMSE, MoCA and FACT-Cog and decreased ReHo values in the bilateral superior frontal gyrus (medial), middle frontal gyrus, left inferior frontal gyrus (orbital part) and increased ReHo values in the bilateral insula and caudate. Compared with HCs, patients receiving PeCC demonstrated decreased ReHo values in the right superior frontal gyrus (dorsolateral), left superior frontal gyrus (medial orbital), middle frontal gyrus, insula and rectus gyrus while patients receiving PaCC presented increased ReHo values in the right rolandic operculum, left insula and right caudate. Compared with patients receiving PaCC, patients receiving PeCC had decreased ReHo values in the left superior frontal gyrus (orbital part), middle frontal gyrus and increased ReHo values in the left inferior temporal gyrus, lingual gyrus. Moreover, positive relationships were found between ReHo values of the left and right superior frontal gyrus (medial) and the total scores of FACT-Cog in the patient group.
UNASSIGNED: The findings provided evidences that carboplatin-based chemotherapy could cause CICI accompanied by functional changes in the prefrontal cortex, insula, caudate. These might be the pathophysiological basis for CICI of NSCLC patients and were affected by the differences of chemotherapeutic agent administration through different biological mechanisms.
摘要：
未经批准：化疗引起的认知障碍（CICI），称为“化学路线”，在施用化疗剂后的癌症患者中非常普遍。然而,CICI潜在的病理生理机制尚不清楚.本研究旨在探讨接受不同化疗方案的非小细胞肺癌(NSCLC)患者脑功能变化及相关认知障碍。
UNASSIGNED：共招募了49例NSCLC患者（25例接受培美曲塞联合卡铂化疗（PeCC）和24例接受紫杉醇联合卡铂化疗（PaCC））和61例健康对照（HCs），并进行了静息状态功能磁共振成像（rs-fMRI）扫描，以及认知功能测试，包括迷你精神状态考试（MMSE），蒙特利尔认知评估（MoCA）癌症治疗的功能评估-认知功能(FACT-Cog)。通过区域同质性（ReHo）值测量脑功能活动，计算和组间比较。此外,评估了改变的脑区ReHo值与认知量表评分之间的关联.
未经证实：NSCLC患者显示MMSE评分降低，MoCA和FACT-Cog以及双侧额上回（内侧）ReHo值降低，额中回,左额下回（眶部）和双侧脑岛和尾状部ReHo值增加。与HC相比，接受PeCC的患者显示右额上回（背外侧）的ReHo值降低，左额上回（眼眶内侧），额中回,当接受PaCC的患者在右罗兰管壳中出现ReHo值增加时，左岛和右尾状.与接受PaCC的患者相比，接受PeCC的患者左额上回（眶部）的ReHo值降低，左额下回和增加的ReHo值，舌回。此外，患者组左右额上回(内侧)的ReHo值与FACT-Cog总分呈正相关.
UNASSIGNED：这些发现提供了证据，证明以卡铂为基础的化疗可引起CI，并伴有前额叶皮质的功能改变，脑岛,尾状.这些可能是NSCLC患者CI的病理生理基础，并通过不同的生物学机制受到化疗药物施用差异的影响。
UNASSIGNED：共招募了49例NSCLC患者（25例接受培美曲塞联合卡铂化疗（PeCC）和24例接受紫杉醇联合卡铂化疗（PaCC））和61例健康对照（HCs），并进行了静息状态功能磁共振成像（rs-fMRI）扫描，以及认知功能测试，包括迷你精神状态考试（MMSE），蒙特利尔认知评估（MoCA）癌症治疗的功能评估-认知功能(FACT-Cog)。通过区域同质性（ReHo）值测量脑功能活动，计算和组间比较。此外,评估了改变的脑区ReHo值与认知量表评分之间的关联.
未经证实：NSCLC患者显示MMSE评分降低，MoCA和FACT-Cog以及双侧额上回（内侧）ReHo值降低，额中回,左额下回（眶部）和双侧脑岛和尾状部ReHo值增加。与HC相比，接受PeCC的患者显示右额上回（背外侧）的ReHo值降低，左额上回（眼眶内侧），额中回,当接受PaCC的患者在右罗兰管壳中出现ReHo值增加时，左岛和右尾状.与接受PaCC的患者相比，接受PeCC的患者左额上回（眶部）的ReHo值降低，左额下回和增加的ReHo值，舌回。此外，患者组左右额上回(内侧)的ReHo值与FACT-Cog总分呈正相关.
UNASSIGNED：这些发现提供了证据，证明以卡铂为基础的化疗可引起CI，并伴有前额叶皮质的功能改变，脑岛,尾状.这些可能是NSCLC患者CI的病理生理基础，并通过不同的生物学机制受到化疗药物施用差异的影响。
